This supports that HMGB1 functions as a potent upstream regulator of a well-established NF-κB–MRPs-therapy resistance axis, further solidifying HMGB1’s position as a central and versatile driver of therapy molecular resistance in cancer. Here, NFKB1 is linked to cancer.